Press Releases | Alexion Pharmaceuticals, Inc

About Alexion
Patient Focus
Products
Research & Development
Responsibility
Careers
Select a Country
- North America
  - Canada
  - USA
- Latin America
  - Argentina
  - Brazil
  - Colombia
  - Mexico
- Europe, the Middle East & Africa
  - Alexion Europe
  - Belgium
  - Denmark
  - France
  - Germany
  - Ireland
  - Italy
  - Netherlands
  - Norway
  - Russia
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - UAE
  - UK
- Asia Pacific
  - Australia
  - China
  - India
  - Japan
Investors
News
Contact

Home
»
Newsroom
»
Press Releases

Press Releases

Press Releases

Alexion to Report Fourth Quarter and Full Year 2018 Results on Monday, February 4, 2019
January 7, 2019
HTML PDF
Alexion to Present at the 37th Annual J.P. Morgan Healthcare Conference
January 2, 2019
HTML PDF
Alexion to Present at the Goldman Sachs 11th Annual Healthcare CEO Conference
December 21, 2018
HTML PDF
Alexion Receives Early FDA Approval for ULTOMIRIS™ (Ravulizumab-cwvz) in Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)
December 21, 2018
HTML PDF
Comprehensive Positive Phase 3 Data for Alexion’s ALXN1210 in Patients with Paroxysmal Nocturnal Hemoglobinuria Presented at American Society of Hematology (ASH) Annual Meeting and Published in Blood
December 3, 2018
HTML PDF
Alexion to Present at the Evercore ISI Healthcare Conference
November 20, 2018
HTML PDF
Alexion to Present at Credit Suisse’s 27th Annual Healthcare Conference
November 7, 2018
HTML PDF
Alexion Completes Acquisition of Syntimmune
November 2, 2018
HTML PDF
Alexion Announces Upcoming Data Presentations at American Society of Hematology Annual Meeting
November 1, 2018
HTML PDF
Alexion Reports Third Quarter 2018 Results
October 24, 2018
HTML PDF